SCHEDULE 13G/A: BlackRock Discloses 6.1% Stake in Recursion Pharmaceuticals
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.1% beneficial ownership stake in Recursion Pharmaceuticals, Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 23,436,636 shares of Recursion Pharmaceuticals, Inc. Class A Common Stock.
- This represents 6.1% of the total outstanding Class A Common Stock of Recursion Pharmaceuticals, Inc.
- BlackRock holds sole voting power over 22,966,295 shares and sole dispositive power over 23,436,636 shares.
- The filing is an Amendment No. 3 to a Schedule 13G, indicating a change or update to BlackRock's previously reported beneficial ownership.
- BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Recursion Pharmaceuticals, Inc.
Sentiment
Score: 5
Explanation: This is a neutral, factual disclosure of beneficial ownership by a large institutional investor. It does not contain positive or negative operational or financial news about the issuer, Recursion Pharmaceuticals, but rather reflects a passive investment stake.
Positives
- This document is a factual ownership disclosure and does not contain specific positive financial or operational news about Recursion Pharmaceuticals. However, the disclosure of a significant institutional stake by BlackRock, a major global asset manager, could be viewed positively by some investors as a sign of institutional confidence in Recursion Pharmaceuticals.
Negatives
- This document is a factual ownership disclosure and does not contain specific negative financial or operational news about Recursion Pharmaceuticals.
Risks
- This document is a factual ownership disclosure and does not detail specific risks related to Recursion Pharmaceuticals' operations or financial health.
Future Outlook
NA
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by BlackRock, Inc.)
Industry Context
This Schedule 13G filing indicates a significant institutional investment by BlackRock, a major global asset manager, in Recursion Pharmaceuticals, a biotechnology company. Such disclosures are common for large asset managers holding passive stakes in publicly traded companies across various industries, including the pharmaceutical and biotech sectors, reflecting their portfolio management activities.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The disclosure of BlackRock's 6.1% stake may be viewed as a vote of confidence from a major institutional investor, potentially influencing other investors' perceptions of Recursion Pharmaceuticals and its stock price.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney that was revoked by the new one. |
| 2024-12-31 | Date of event which requires the filing of this statement (reporting period end date). |
| 2025-01-21 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| 2025-02-05 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
BlackRock, Recursion Pharmaceuticals, Schedule 13G, Beneficial Ownership, Institutional Investor, Class A Common Stock, SEC Filing, Investment Management, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.